Plaque-Phase Mycosis Fungoides Treated with Photodynamic Therapy: Results from 12 Patients

Fernández-Guarino, M.; Harto, A.; Pérez-García, B.; Montull, C.; De Las Heras, E.; Jaén, P.

doi:10.1016/S1578-2190(10)70717-4

Información del artículo

Resumen

Bibliografía

Descargar PDF

Estadísticas

Abstract

Background

Recent years have seen an increase in the off-label use of photodynamic therapy for the treatment of a variety of skin diseases. Plaque-phase mycosis fungoides is among the most promising possibilities for the use of this treatment.

Objectives

To evaluate the treatment of plaque-phase mycosis fungoides with photodynamic therapy and compare the results obtained using fluorescence photography.

Material and methods

We performed a prospective, descriptive, observational study. Twelve patients with 24 lesions were treated with topical methyl aminolevulinate (MAL) under an occlusive dressing for 3 hours, followed by 8 minutes of red light (630 nm, 37 J/ cm2; Aktilite).

Results

Six patients had a complete response, 5 a partial response, and 1 did not respond to treatment. A mean of 5.7 sessions was applied and no side effects were reported. Treatment tolerance was excellent.

Conclusions

Photodynamic therapy with MAL appears to be a good treatment option for patients with plaque-phase mycosis fungoides with a small number of lesions.

Keywords:

Mycosis fungoides

Photodynamic therapy

Methyl aminolevulinate

Resumen

Introducción

La terapia fotodinámica (TFD) está siendo desarrollada en los últimos años en dermatosis diferentes de las aprobadas para su uso. Entre todas ellas, la micosis fungoide (MF) en estadio de placas es una de las más prometedoras.

Objetivos

Evaluar los resultados en el tratamiento de la MF en placas con TFD y correlacionarlos con la fotografía de fluorescencia.

Material y métodos

Llevamos a cabo un estudio prospectivo, descriptivo y observacional. Se seleccionaron un total de 12 pacientes con 24 lesiones que fueron tratados con metilaminolevulinato (MAL) tópico ocluido tres horas y luz roja (630 nm, 37 J/cm2, 8 min, Aktilite®).

Resultados

Un total de 6 pacientes obtuvo respuesta completa, 5 pacientes alcanzaron respuesta parcial y uno no respondió al tratamiento. La media de sesiones aplicadas fue de 5,7 y no se recopilaron efectos secundarios. La tolerancia fue excelente.

Conclusiones

La TFD con MAL parece una buena alternativa terapéutica para los pacientes con MF en placas con escaso número de lesiones.

Palabras clave:

Micosis fungoide

Terapia fotodinámica

Metilaminolevulínico

El Texto completo está disponible en PDF

References

[1.]

E.M. Welch, K. Kelly.

Otras indicaciones dermatológicas del ALAPDT.

Terapia fotodinámica Primera, pp. 89-101

[2.]

K. Svanberg, T. Andersson, D. Killander, I. Wang, U. Stenram, S. Aderson-Engels, et al.

Photodynamic therapy of nonmelanoma malignant tumours of the skin using topical delta-aminolaevulinic acid sensitization and laser irradiation.

Br J Dermatol, 130 (1994), pp. 743-751

Medline

[3.]

P. Wolf, R. Fink-Puches, L. Cerroni, H. Kerl.

Photodynamic therapy for mycosis fungoides after photosensitization with 5-aminolaevulinic acid.

J Am Acad Dermatol, 31 (1994), pp. 678-680

Medline

[4.]

R. Ammann, Th. Hunziker.

Photodynamic therapy for mycosis fungoides after topical photosensitization with 5-aminolaevulinic acid.

J Am Acad Dermatol, 33 (1995), pp. 541

Medline

[5.]

D.W. Edstrom, A.W. Ros, A. Parvit.

Topical 5-aminolaevulinic acid based photodynamic therapy for mycosis fungoides a study of cell proliferation an apoptosis before and after therapy.

J Dermatol Sci, 16 (1998), pp. 229

[6.]

I. Wang, B. Bauer, S. Anderson-Engels.

Photodynamic therapy utilizing delta aminolevulinic acid in non-melanoma skins malignancies of the eyelid and periocular skin.

Acta Oftalm Scan, 77 (1999), pp. 182-188

[7.]

A. Orestein, J. Haik, J. Tamir, E. Winkler, H. Trau, Z. Malik, et al.

Photodynamic therapy of cutaneous lymphoma using 5-aminolevulinic acid topical application.

Dermatol Surg, 26 (2000), pp. 765-769

Medline

[8.]

T. Markham, K. Sheehan, P. Collins.

Topical 5-aminolvulinic acid photodynamic therapy for tumour-stage mycosis fungoides.

Br J Dermatol, 144 (2001), pp. 1262

Medline

[9.]

D.W. Edstrom, A. Portwit, A.M. Ros.

Photodynamic therapy with topical 5-aminolvulinic acid for mycosis fungoides: clinical and histological response.

Acta Derm Venereol, 81 (2001), pp. 184-188

Medline

[10.]

V. Paech, T. Lorenzen, Stoehr, K. Lange, H. Merz, W.N. Meigel, et al.

Remission of a cutaneous mycosis fungoides after topical 5-ALA sensitization and photodynamic therapy in a patient with advanced HIV-infection.

Eur J Med Res, 7 (2002), pp. 477-479

Medline

[11.]

J.A. Leman, D.C. Dick, C.A. Morton.

Topical 5-ALA therapy for the treatment of cutaneous T-cell lymphoma.

Clin Exp Dermatol, 27 (2002), pp. 516-518

Medline

[12.]

E.A. Coors, P. von den Driesch.

Topical photodynamic therapy for patients with therapy-resistant lesions of cutaneous T-cell lymphoma.

J Am Acad Dermatol, 50 (2004), pp. 363-367

http://dx.doi.org/10.1016/S0190 | Medline

[13.]

C. Zane, M. Venturini, R. Sala, P. Calzavara-Pinton.

Photodynamic therapy with methylaminolevulinate as a valuable treatment option for unilesional cutaneous T- cell lymphoma.

Photodermatol Photoinmunol Photomed, 22 (2006), pp. 254-258

[14.]

E. Díez-Recio, B. Zambrano, M.L. Alonso, E. De Eusebio, M. Martín, J. Cuevas, et al.

Topical 5-aminolaevulinic acid photodynamic therapy for the treatment of unilesional mycosis fungoides, a report of two cases and review of the literature.

Int J Dermatol, 47 (2008), pp. 410-413

http://dx.doi.org/10.1111/j.1365-4632.2008.03177.x | Medline

[15.]

W. Boehnke, R. Koning, A. Ruck, R. Kaufmann, W. Sterry.

In vitro and in vivo effects of photodynamic therapy in cutaneous T cell lymphoma.

Acta Dermvenereol, 74 (1994), pp. 201-205

[16.]

K. Rittenhouse-Diakun, H. Van Leengoed, J. Morgan, E. Hryhorenko, G. Paszkiewicz, J.E. Whitaker, et al.

The role of transferrin receptor (CD71) in photodynamic therapy of activated and malignant lymphocytes using the hem precursor delta-aminolaevulinic acid (ALA).

Photochem Photobiol, 61 (1995), pp. 523-528

Medline

[17.]

S.J. Whittaker, F.M. Foss.

Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezar syndrome variants of cutaneous T-cell lymphoma.

Cancer Treat Rev, 33 (2007), pp. 146-160

http://dx.doi.org/10.1016/j.ctrv.2006.08.006 | Medline

Indexada en:

Síguenos:

Indexada en:

Síguenos:

Suscríbase a la newsletter